Sugi Predict

Sugi Predict / Compounds / SCHEMBL1384633

SCHEMBL1384633

SCHEMBL1384633

NC(=O)c1cccc(N2CCN(C(=O)c3[nH]c(S)nc3-c3ccccc3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ MGLL Q99685 2/20 0.46
▸ PARP14 Q460N5 4/20 0.46
▸ PARP10 Q53GL7 2/20 0.46
▸ CHEK2 O96017 2/20 0.45
▸ POLB P06746 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SLC6A7 Q99884 1/20 0.44
▸ PDE3B Q13370 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ CKS1B P61024 1/20 0.43
▸ SKP1 P63208 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ TACR3 P29371 1/20 0.43
▸ TNKS O95271 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1385439 0.89 USP2 (0.48) USP2MAPK1LMNATSHRMAPT
SCHEMBL1382078 0.85 TAAR1 (0.56) USP2MAPK1LMNATSHRMAPT
SCHEMBL1383039 0.85 CHEK2 (0.46) USP2MAPK1LMNATSHRMAPT
SCHEMBL5758459 0.85 MGLL (0.47) USP2MAPK1LMNATSHRMAPT
SCHEMBL1381981 0.84 SMO (0.48) USP2MAPK1LMNATSHRMAPT
SCHEMBL1382704 0.77 USP2 (0.51) USP2MAPK1LMNATSHRMAPT
SCHEMBL1383839 0.76 LMNA (0.48) USP2MAPK1LMNATSHRMAPT
SCHEMBL1382338 0.76 USP2 (0.48) USP2MAPK1LMNATSHRMAPT
SCHEMBL1379374 0.76 TSHR (0.47) USP2MAPK1LMNATSHRMAPT
SCHEMBL1380130 0.76 USP2 (0.47) USP2MAPK1LMNATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4805813-B2 — — 2011-11-02 — — JP claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 — — EP claimed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 — — US claimed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 — — WO claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 — — EP disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 — — US disclosed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC USP2 2195/4885MAPK1 4390/4885LMNA 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.